AI Science Tracker

Deep learning on routine pathology slides prescreens FGFR-altered bladder cancers in a global study

Janssen Research & Development, LLC (Johnson & Johnson) · 1 Jun 2024 · medicine

Discovery

Deep learning on routine pathology slides prescreens FGFR-altered bladder cancers in a global study

A deep-learning device analyzed routine H&E whole-slide images to estimate whether advanced urothelial tumors carried selected FGFR2/FGFR3 alterations used for erdafitinib eligibility. In a separate 350-slide retrospective validation set, the device achieved 88.7% sensitivity and 31.8% specificity; it was also prospectively integrated into a non-interventional study spanning 89 sites in nine countries. The paper projected a 28.7% reduction in molecular tests assuming 15% biomarker prevalence; that estimate was simulated, not a measured population-level reduction.

Technology: FGFR Device, a multi-instance-learning attention model with a convolutional neural-network backbone

Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: prospective or independent check
  • Tested: In a separate 350-slide retrospective validation set, the device achieved 88.7% sensitivity and 31.8% specificity; it was also prospectively integrated into a non-interventional study spanning 89 sites in nine countries.
  • Still unknown: The 350-slide retrospective validation set was deliberately enriched (150 FGFR-positive and 200 negative; 43% prevalence), and the device fell slightly short of the prespecified 90% sensitivity target. Prospective real-time workflow validation covered only 17 samples in one month (15 predictions; two quality-control failures); production deployment reported 24 samples, with only 20 receiving molecular testing. The 28.7% test reduction is a simulation assuming 15% prevalence, not an observed clinical outcome. This is prescreening support, not a stand-alone diagnosis or evidence of patient benefit.
  • AI role: Trained on more than 3,000 urothelial-cancer slides with molecular test labels, the deep-learning model inferred selected FGFR alteration status from H&E images and returned a likelihood for prescreening before confirmatory molecular testing. The device was prospectively integrated into a non-interventional study workflow; molecular tests remained the reference standard.

Evidence sources: https://www.nature.com/articles/s41467-024-49153-9.pdf

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 30 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 4/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.